Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis

AIM To ascertain whether cholestasis affects the expression of two CYP3A isoforms (CYP3A1 and CYP3A2) and of pregnane X receptor (PXR) and constitutive androstane receptor (CAR). METHODS Cholestasis was induced by bile duct ligation in 16 male Wistar rats; whereas 8 sham-operated rats were used as controls. Severity of cholestasis was assessed on histological examination of liver sections, and serum concentrations of albumin, AST, ALT, GGT, ALPK and bilirubin. Gene and protein expressions of PXR, CAR, CYP3A1 and CYP3A2 were assessed by means of qRT-PCR and Western blot, respectively. Alterations in CYP3A activity were measured by calculating the kinetic parameters of 4-OH and 1’-OH-midazolam hydroxylation, marker reactions for CYP3A enzymes. RESULTS The mRNA and protein expression of CYP3A1 increased significantly in mild cholestasis (P < 0.01). At variance, mRNA and protein expression of CYP3A2 didn’t change in mild cholestasis, whereas the expression and activity of both CYP3A1 and CYP3A2 decreased dramatically when cholestasis became severe. Consistently with these observations, the nuclear expression of both PXR and CAR, which was measured because they both translocate into the cell nucleus after their activation, virtually disappeared in the late stage of cholestatic injury, after an initial increase. These results indicate that early- and late-stage cholestasis affects CYP3A-mediated drug metabolism differently, probably as consequence of the different activation of PXR and CAR. CONCLUSION Early- and late-stage cholestasis affects CYP3A-mediated drug metabolism differently. PXR and CAR might be targeted therapeutically to promote CYP3A-mediated liver detoxification.

[1]  J. Staudinger,et al.  Nuclear-receptor–mediated regulation of drug– and bile-acid–transporter proteins in gut and liver , 2013, Drug metabolism reviews.

[2]  M. Trauner,et al.  Nuclear receptors as new perspective for the management of liver diseases. , 2011, Gastroenterology.

[3]  P. Thomas,et al.  Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[4]  R. Poupon Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. , 2012, Clinics and research in hepatology and gastroenterology.

[5]  V. Ling,et al.  Hepatic bile acid metabolism and expression of cytochrome P450 and related enzymes are altered in Bsep−/− mice , 2014, Molecular and Cellular Biochemistry.

[6]  E. Gonzalez-Sanchez,et al.  Nuclear Receptors in Acute and Chronic Cholestasis , 2015, Digestive Diseases.

[7]  A. Mendeloff Chronic liver disease. , 1956, Sinai Hospital journal.

[8]  K. Byth,et al.  Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. , 1995, Biochemical pharmacology.

[9]  M. Downes,et al.  FXR and PXR: Potential therapeutic targets in cholestasis , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  M. Ene,et al.  Pharmacokinetics of Nifedipine After Oral Administration in Chronic Liver Disease , 1987, Journal of clinical pharmacology.

[11]  G. Farrell,et al.  Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: Relevance to drug metabolism in experimental cholestasis , 1996, Journal of gastroenterology and hepatology.

[12]  T. Roskams,et al.  Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats , 2014, Hepatology.

[13]  G. Farrell,et al.  Downregulation of male‐specific cytochrome P450s 2C11 and 3A2 in bile duct–ligated male rats: Importance to reduced hepatic content of cytochrome P450 in cholestasis , 1995, Hepatology.

[14]  K. Zatloukal,et al.  Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[15]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[16]  P. Palatini,et al.  Pharmacokinetic drug interactions in liver disease: An update. , 2016, World journal of gastroenterology.

[17]  R. Evans,et al.  A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. , 2004, Molecular pharmacology.

[18]  C. Favre,et al.  Inhibitory Effect of Short-Term Bile Duct Ligation on Hepatic Cytochrome P450 of Bile Acid-Depleted Rats , 2001, Pathobiology.

[19]  Marco Migliorati,et al.  Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. , 2011, Biochimica et biophysica acta.

[20]  H. Rogers,et al.  Enzyme Inhibition , 1954, Nature.

[21]  D. Nie,et al.  Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. , 2012, Biochemical pharmacology.

[22]  R. Evans,et al.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Pávek Pregnane X Receptor (PXR)-Mediated Gene Repression and Cross-Talk of PXR with Other Nuclear Receptors via Coactivator Interactions , 2016, Front. Pharmacol..

[24]  G. Albertin,et al.  Differential Effect of Liver Cirrhosis on the Pregnane X Receptor–Mediated Induction of CYP3A1 and 3A2 in the Rat , 2014, Drug Metabolism and Disposition.

[25]  Kaoru Kobayashi,et al.  Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. , 2002, Biochemical pharmacology.

[26]  K. Okazaki,et al.  Effect of biliary obstruction and internal biliary drainage on hepatic cytochrome P450 isozymes in rats. , 2008, World journal of gastroenterology.

[27]  Yi-Tong Liu,et al.  Drugs as CYP3A Probes, Inducers, and Inhibitors , 2007, Drug metabolism reviews.

[28]  V. Tahan,et al.  Time course of collagen peak in bile duct-ligated rats , 2011, BMC gastroenterology.

[29]  T. Willson,et al.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Li Wang,et al.  Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet? , 2016, Annual review of pharmacology and toxicology.

[31]  J. Villeneuve,et al.  Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis. , 2000, Canadian journal of physiology and pharmacology.

[32]  R. Evans,et al.  Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Orlando,et al.  Severe Liver Cirrhosis Markedly Reduces AhR-Mediated Induction of Cytochrome P450 in Rats by Decreasing the Transcription of Target Genes , 2013, PloS one.

[34]  Taosheng Chen,et al.  Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk , 2016, Expert opinion on drug metabolism & toxicology.

[35]  G. Hirschfield,et al.  Pathogenesis of cholestatic liver disease and therapeutic approaches. , 2010, Gastroenterology.

[36]  P. Thomas,et al.  Generation of specific antibodies and their use to characterize sex differences in four rat P450 3A enzymes following vehicle and pregnenolone 16alpha-carbonitrile treatment. , 2006, Archives of biochemistry and biophysics.

[37]  G. Farrell,et al.  Microsomal protein synthesis and induction of cytochrome P-450 in cirrhotic rat liver. , 1984, The Australian journal of experimental biology and medical science.

[38]  A. Baghdasaryan,et al.  Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases , 2013, Clinics in liver disease.

[39]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[40]  J. Boyer,et al.  Molecular pathogenesis of cholestasis. , 2012, The New England journal of medicine.

[41]  Sabine Weiskirchen,et al.  Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis , 2015, Journal of visualized experiments : JoVE.

[42]  I. Dimauro,et al.  A simple protocol for the subcellular fractionation of skeletal muscle cells and tissue , 2012, BMC Research Notes.

[43]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.